Summit Therapeutics Inc.

Summit Therapeutics Inc.

290.00
MXN
0.00
(0.00%)
-19.29EPS
Mar 18Next Earn

Important Dates

Summit Therapeutics Inc's next confirmed earnings release is scheduled for March 18, 2027.

Earnings Date3/18/2027

Share Statistics

As of September 30, 2026, Summit Therapeutics Inc has 799.73M shares outstanding.

Shares Outstanding799.73M

Financial Position

As of September 30, 2026, Summit Therapeutics Inc maintains a current ratio of 5.99, meaning it holds 6.0x the short-term assets needed to cover near-term liabilities.

Current Ratio5.99
Quick Ratio5.71
Debt / Equity3.54
Debt / EBITDA-0.02

Financial Efficiency

Over the twelve months ended September 30, 2026, Summit Therapeutics Inc posted a negative return on equity (ROE) of -220.01, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -174.46, reflecting losses generated across the asset base. The company generates approximately - - in revenue per employee across its workforce of 265.00, a quick read on workforce productivity versus industry peers.

Return on Equity (ROE)-220.01
Return on Assets (ROA)-174.46
Employee Count265.00

Stock Price Statistics

As of the close on October 27, 2026, Summit Therapeutics Inc's stock has declined approximately 19.44% over the past 52 weeks.

52-Week Price Change-19.44%

Income Statement

MXN

Over the twelve months ended September 30, 2026, Summit Therapeutics Inc generated - - in revenue and converted that into -15.04B in net income, yielding earnings per share of -19.29. EBITDA reached -15.44B, while operating income came in at -15.44B.

Operating Income-15.44B
Pretax Income-15.03B
Net Income-15.04B
EBITDA-15.44B
EBIT-15.44B
Earnings Per Share (EPS)-19.29

Balance Sheet

MXN

As of September 30, 2026, Summit Therapeutics Inc holds 11.37B in cash and equivalents against 360.82M in total debt, resulting in a net debt position of -2.72B. Total book value stands at 10.20B, with working capital of 9.94B providing operational flexibility.

Cash & Cash Equivalents11.37B
Total Debt360.82M
Net Debt-2.72B
Equity (Book Value)10.20B
Book Value Per Share12.75
Working Capital9.94B

Cash Flow

MXN

Summit Therapeutics Inc produced -9.48B in operating cash flow over the twelve months ended September 30, 2026. After subtracting -30.95M in capital expenditures, free cash flow totaled -9.51B - equivalent to -12.20 per share.

Operating Cash Flow-9.48B
Capital Expenditures-30.95M
Free Cash Flow-9.51B
FCF Per Share-12.20